Targeting treatments to improve cognitive function in mood disorder: Suggestions from trials using erythropoietin

Journal of Clinical Psychiatry

Volumn 77, Issue 12, 2016, Pages e1639-e1646

  Miskowiak, Kamilla Woznica ^a   John Rush, A ^b   Gerds, Thomas A ^c   Vinberg, Maj ^a   Kessing, Lars V ^a  

^a Rigshospitalet   (Denmark)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN;

ADULT; AGE; AGED; ARTICLE; BIPOLAR DISORDER; COGNITION; COGNITIVE AND PHYSICAL FUNCTIONING QUESTIONNAIRE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; EDUCATIONAL STATUS; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEMORY DISORDER; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECALL; RECEIVER OPERATING CHARACTERISTIC; REY AUDITORY VERBAL LEARNING TEST; SELF REPORT; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; VERBAL MEMORY; COGNITIVE DYSFUNCTION; COMPLICATION; MEMORY DISORDERS; MIDDLE AGED; MOOD DISORDER; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADULT; AGED; BIPOLAR DISORDER; COGNITIVE DYSFUNCTION; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; MOOD DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); YOUNG ADULT;

EID: 85007609246     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15m10480     Document Type: Article

References (47)

1. Bora E, Harrison BJ, Y el M, et al. Cognitive impairment in euthymic major depressive disorder: A meta-Analysis. Psychol Med. 2013;43(10):2017-2026. doi:10.1017/S0329171202085
2. Kurtz MM, Gerraty RT. A meta-Analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state. Neuropsychology. 2009;23(5):551-562. doi:10.1037/a01627
3. Depp CA, Mausbach BT, Harmell AL, et al. Meta-Analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disord. 2012;14(3):217-226. doi:10.1/j.139-5618.2012.0101.x
4. Jaeger J, Berns S, Uzelac S, et al. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145(1):39-48. doi:10.1016/j.psychres.205.1.01
5. Dias VV, Balanz Martinez V, Soeiro-de-Souza MG, et al. Pharmacological approaches in bipolar disorders and the impact on cognition: A critical overview. Acta Psychiatr Scand. 2012;126(5):315-331. doi:10.1/j.160-047.2012.01910.x
6. Carvalho AF, Miskowiak KK, Hyphantis TN, et al. Cognitive dysfunction in depression-pathophysiology and novel targets. CNS Neurol Disord Drug Targets. 2014;13(10):1819-1835. doi:10.2174/1871527313614130203627
7. Demant KM, Vinberg M, Kessing LV, et al. Effects of short-Term cognitive remediation on cognitive dysfunction in partially or fully remitted individuals with bipolar disorder: results of a randomised controlled trial. PLoS One. 2015;10(6):e0127955. doi:10.1371/journal.pone.012795
8. Porter RJ, Bowie CR, Jordan J, et al. Cognitive remediation as a treatment for major depression: A rationale, review of evidence and recommendations for future research. Aust N Z J Psychiatry. 2013;47(12):1165-1175. doi:10.17/04867413502090
9. Sol B, Jimez E, Martinez-Aran A, et al. Cognition as a target in major depression: new developments. Eur Neuropsychopharmacol. 2015;25(2):231-247. doi:10.1016/j.euroneuro.2014.12.04
10. Schaefer J, Giangrande E, Weinberger DR, et al. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr Res. 2013;150(1):42-50. doi:10.1016/j.schres.2013.07.09
11. Reichenberg A, Harvey PD, Bowie CR, et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull. 2009;35(5):1022-1029. doi:10.1093/schbul/sbn04
12. Rund BR, Sundet K, Asbjnsen A, et al. Neuropsychological test profiles in schizophrenia and non-psychotic depression. Acta Psychiatr Scand. 2006;113(4):350-359. doi:10.1/j.160-047.205.0626.x
13. Gualtieri CT, Morgan DW. The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: An unaccounted source of variance in clinical trials. J Clin Psychiatry. 2008;69(7):1122-1130. doi:10.4088/JCP.v69n0712
14. Demant KM, Vinberg M, Kessing LV, et al. Assessment of subjective and objective cognitive function in bipolar disorder: Correlations, predictors and the relation to psychosocial function. Psychiatry Res. 2015;229(1-2):565-571. doi:10.1016/j.psychres.2015.05.02
15. Jensen JH, Sttrup MM, Nayberg E, et al. Optimising screening for cognitive dysfunction in bipolar disorder: validation and evaluation of objective and subjective tools. J Affect Disord. 2015;187(10):10-19. doi:10.1016/j.jad.2015.07.039
16. Ott CV, Bjertrup AJ, Jensen JH, et al. Screening for cognitive dysfunction in unipolar depression: validation and evaluation of objective and subjective tools. J Affect Disord. 2016;190:607-615. doi:10.1016/j.jad.2015.10.059
17. Burdick KE, Braga RJ, Nnadi CU, et al. Placebocontrolled adjunctive trial of pramipexole in patients with bipolar disorder: Targeting cognitive dysfunction. J Clin Psychiatry. 2012;73(1):103-112. doi:10.4088/JCP.11m07299
18. Torrent C, Bonnin CdelM, Martez-Ar A, et al. Efficacy of functional remediation in bipolar disorder: A multicenter randomized controlled study. Am J Psychiatry. 2013;170(8):852-859. doi:10.176/api.ajp.2012.12070971
19. Bonnin CM, Reinares M, Martez-Ar A, et al; CIBERSAM Functional Remediation Group. Effects of functional remediation on neurocognitively impaired bipolar patients: enhancement of verbal memory. Psychol Med. 2016;46(2):291-301. doi:10.1017/S0329171501713
20. Iosifescu DV, Moore CM, Deckersbach T, et al. Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: A proof-ofconcept study. CNS Neurosci Ther. 2009;15(4):309-319. doi:10.1/j.175-5949.209.090.x
21. Miskowiak KW, Ehrenreich H, Christensen EM, et al. Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: A double-blind, randomized, placebo-controlled phase 2 trial. J Clin Psychiatry. 2014;75(12):1347-1355. doi:10.4088/JCP.13m08839
22. Svendsen AM, Kessing LV, Munkholm K, et al. Is there an association between subjective and objective measures of cognitive function in patients with affective disorders? Nord J Psychiatry. 2012;66(4):248-253. doi:10.3109/0803948.201.626870
23. Miskowiak KW, Vinberg M, Christensen EM, et al. Recombinant human erythropoietin for treating treatment-resistant depression: A double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology. 2014;39(6):1399-1408. doi:10.1038/np.2013.35
24. Miskowiak KW, Vinberg M, Macoveanu J, et al. Effects of erythropoietin on hippocampal volume and memory in mood disorders. Biol Psychiatry. 2015;78(4):270-277. doi:10.1016/j.biopsych.2014.12.013
25. Ktner A, Grube S, El-Kordi A, et al. Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance in schizophrenia. Mol Med. 2012;18:1029-1040. doi:10.219/molmed.2012.0190
26. Miskowiak KW, Vinberg M, Harmer CJ, et al. Erythropoietin: A candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology (Berl). 2012;219(3):687-698. doi:10.107/s0213-01-251-1
27. Sargin D, Friedrichs H, El-Kordi A, et al. Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best Pract Res Clin Anaesthesiol. 2010;24(4):573-594. doi:10.1016/j.bpa.2010.10.05
28. Miskowiak KW, Vinberg M, Harmer CJ, et al. Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials. 2010;11:97. doi:10.186/1745-6215-1-97
29. Posternak MA, Young D, Sheeran T, et al. Assessing past treatment history: Test-retest reliability of the Treatment Response to Antidepressant Questionnaire. J Nerv Ment Dis. 2004;192(2):95-102. doi:10.1097/01.nmd.010280.19284.47
30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62. doi:10.136/jnp.23.1.56
31. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435. doi:10.192/bjp.13.5.429
32. Fava M, Iosifescu DV, Pedrelli P, et al. Reliability and validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire. Psychother Psychosom. 2009;78(2):91-97. doi:10.159/0201934
33. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A. 2000;97(19):10526-10531. doi:10.1073/pnas.97.19.10526
34. Ehrenreich H, Degner D, Meller J, et al. Erythropoietin: A candidate compound for neuroprotection in schizophrenia. Mol Psychiatry. 2004;9(1):42-54.
35. Ehrenreich H, Hinze-Selch D, Stawicki S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry. 2007;12(2):206-220. doi:10.1038/sj.mp.401907
36. Ehrenreich H, Fischer B, Norra C, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007;130(pt 10):2577-2588. doi:10.1093/brain/awm203
37. Schmidt M. Rey Auditory Verbal Learning Test-A Handbook. Los Angeles, CA: Western Psychological Services; 2004.
38. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571. doi:10.101/archpsyc.1961.017101203104
39. Strauss E, Sherman E, Spreen O. A Compendium of Neuropsychological Tests. Administration, Norms, and Commentary. 3rd ed. Oxford, UK: Oxford University Press; 2006.
40. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford, UK: Oxford University Press; 2003.
41. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics. 1988;44(3):837-845. doi:10.2307/2531595
42. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
43. Forcada I, Mur M, Mora E, et al. The influence of cognitive reserve on psychosocial and neuropsychological functioning in bipolar disorder. Eur Neuropsychopharmacol. 2015;25(2):214-222. doi:10.1016/j.euroneuro.2014.07.018
44. Purdon S. The Screen for Cognitive Impairment in Psychiatry: Administration and Psychometric Properties. Edmonton, Alberta: PNL Inc; 2005.
45. Grande I, Berk M, Birmaher B, et al. Bipolar disorder. Lancet. 2016;387(10027):1561-1572. doi:10.1016/S0140-6736(15)0241-X
46. Bonn CM, Martez-Ar A, Torrent C, et al. Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: A long-Term, follow-up study. J Affect Disord. 2010;121(1-2):156-160. doi:10.1016/j.jad.209.05.014
47. Martinez-Aran A, Vieta E, Torrent C, et al. Functional outcome in bipolar disorder: The role of clinical and cognitive factors. Bipolar Disord. 2007;9(1-2):103-113.